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Background: In vitro studies have suggested the corneal cytotoxicity of third-generation 
fluoroquinolone levofloxacin (LVFX) and fourth-generation fluoroquinolone moxifloxacin 
hydrochloride (MFLX) among fluoroquinolone antibacterial eye drops. This study investigated 
the effects of these two eye drops on the human cornea in vivo.
Methods: We evaluated 30 healthy adults (19 men and 11 women, 38.3 ± 6.3 years old). Each 
subject received an LVFX ophthalmic solution 0.5% in one eye and an MFLX ophthalmic solu-
tion 0.5% in the other eye three times daily for 7 days. Functional and morphological corneal 
changes before and after instillation were evaluated through ophthalmic examinations including 
breakup time of tear film (BUT) as measured by fluorescein staining and DR-1, Schirmer I test, 
Heidelberg Retina Tomograph II Rostock Cornea Module (HRTII-RCM), specular microscope, 
and Pentacum examination.
Results: Both the LVFX and MFLX groups had no significant change in each examination 
before and after instillation. There was also no statistically significant difference in measurements 
after the 7-day instillation between the groups.
Conclusion: Our study results suggest that as with LVFX, MFLX used in a normal clinical 
setting is unlikely to cause any obvious adverse effects on human normal cornea.
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Introduction
Fluoroquinolone antibacterial eye drops are a broad spectrum antibacterial that 
effectively inhibit two enzymes, bacterial topoisomerase IV and topoisomerase II (DNA 
gyrase). They are widely used for ocular infections and perioperative prophylaxis in 
ophthalmic surgery because of these advantages.
Fluoroquinolones are relatively safe, although they have shown inhibitory activity 
against mammalian topoisomerase II, which is related to bacterial DNA gyrase.1 It is 
therefore also possible that fluoroquinolone antibacterial eye drops have some influence 
on corneal cells. In vitro studies of fluoroquinolone using human corneal keratocyte 
cultures suggest that levofloxacin (LVFX) and moxifloxacin (MFLX) may be cytotoxic.2 
However, the effects of these drugs in vivo remain to be determined.
In the present study, using a moxifloxacin ophthalmic solution 0.5% (MFLX) 
(Vegamox; Alcon Japan, Tokyo, Japan), a fourth-generation fluoroquinolone with 
excellent aqueous penetration3,4 and a levofloxacin ophthalmic solution 0.5% (LVFX) 
(Cravit, Santen Pharmaceutical, Osaka, Japan), a third-generation fluoroquinolone used 
widely in Japan, we investigated the effects of these fluoroquinolone antibacterial eye 
drops on normal human cornea in terms of the break-up time of tear film (BUT) and Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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the morphological appearance of the corneal epithelium, 
stroma, and endothelium.
Methods
The protocol for this research project has been approved 
by the Ethics Committee of Tohoku University Graduate 
School of Medicine and it conforms to the provisions of the 
Declaration of Helsinki in 1995. This study gave informed 
consent and patient anonymity was preserved. We recruited 
40 healthy adult volunteers from the public at the Department 
of Ophthalmology, Tohoku University Graduate School of 
Medicine. Among them, 30 volunteers were judged eligible 
for participation through the screening test and, after 
providing informed consent, they were randomly assigned to 
two groups. Subjects in one group received MFLX in their 
left eye or LVFX in their right eye and those in the other 
group received MFLX in their right eye or LVFX in their 
left eye. The study was conducted in a single blind fashion 
where only the investigator was masked to the allocated 
study eye drops.
Subjects received one drop of MFLX or LVFX in either 
eye three times a day for 7 days. Before and after instillation 
of the study eye drops, the effects of each study drug on the 
corneal epithelium, stroma, and endothelium were evaluated 
through the method described later in this paper.
The exclusion criteria for this study included a history 
of hypersensitivity to fluoroquinolones, corneal epithelial 
defects (including superficial punctate keratopathy (SPK)), 
conjunctivitis, a history of herpetic keratitis, abnormal 
lacrimation (a Schirmer I test measurement of 5 mm or less 
or a BUT measurement of 5 seconds or less), use of any 
antibacterial eye drops within 1 week of study entry, use 
of eye drops other than the study eye drops, use of contact 
lenses within 2 weeks of study entry, intraocular pressure of 
21 mmHg or more, inability of the subject to provide written 
informed consent, and any other reason judged ineligible for 
participation in the study by the investigator.
Study eye drops
The eye drops used in the present study were MFLX and 
LVFX, both of which did not contain benzalkonium chloride 
and are commercially available in Japan.
Evaluations
Two weeks before study entry and on the last day of 
study (after 7 days of instillation), subjects under-
went a general ocular examination including slit-lamp 
microscopy, evaluation of the influence on the corneal 
epithelium by fluorescein staining,5 BUT measurement 
with fluorescein staining and with a DR-1 (Tear film lipid 
layer interferometry system, Kowa, Nagoya, Japan), and a 
Schirmer I test. In addition to these tests, corneal function 
and morphological changes were observed using a specular 
microscope (Topcon SP-3000P, Topcon Ltd, Tokyo, Japan), 
Pentacam (Oculus, Wetzlar, Germany), and Heidelberg 
Retina Tomograph II Rostock Cornea Module (HRTII-
RCM) (Heidelberg Engineering, Dossenheim, Germany). 
On the last day of the study, treatment compliance and the 
development of any adverse events were confirmed. In 
addition, subjects were asked to complete a questionnaire to 
assess their satisfaction with the study eye drops (irritating 
sensation and drop comfort upon instillation) using a visual 
analog scale (VAS) (0 to 100 mm). Table 1 summarizes the 
observation items and details of each item.
The DR-1 is a system designed to observe interference 
colors generated by a specular light from the tear film lipid 
layer and classify the status of dry eye into five grades for 
evaluation. Normal eyes exhibit a gray interference color 
that is distributed uniformly, whereas dry eyes frequently 
show two or more interference colors (Grade 3, 4, and 5). In 
severe dry eyes, tear production with blinking is inadequate 
and the corneal surface is partially exposed (Grade 5).6 
HRTII-RCM allows noninvasive in vivo observation of 
the corneal microstructure including epithelium, stroma, 
and endothelium.7 The range of the captured HRTII-RCM 
picture was 400 × 400 µm, and the resolution power of the 
image was 384 × 384 pixels. The Pentacam is a rotating 
single Scheimpflug camera system. It computes anterior 
and posterior curvatures and provides complete corneal 
pachymetry of the entire cornea.
Statistical analysis
Subject data were entered and analyzed using the following 
software: Microsoft Excel 2003 (Microsoft Corpora-
tion, Redmond, WA) and JMP Version 6 (SAS Institute 
Japan Ltd, Tokyo, Japan).
Comparison of the two study eye drops was performed 
by the paired t-test. Measurements are represented in 
mean ± standard deviation. The grading of the tear film lipid 
layer was made with the Mann–Whitney U-test. Comparison 
of the patients with epithelial defects before and after treat-
ment was performed using Fisher’s exact test.
Results
The 30 subjects consisted of 19 men and 11 women (mean 
age ± standard deviation: 38.3 ± 6.3 years). Throughout the Clinical Ophthalmology 2010:4
Table 1 The observation items and details of each item
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Informed consent ○
Subject background ○
Concomitant drugs ○ ○
Visual acuity test ○ ○
Treatment compliance ○
Slit-lamp microscopy ○ ○ ✓ Observation of the corneal epithelium
Anterior-segment pictures 
(fluorescein staining) (BUT)
○ ○ ✓ Evaluation of the influence on the corneal epithelium
Specular microscope ○ ○ ✓ Observation of the corneal endothelium. Measurement of 
endothelial cell density, and coefficient of variation (CV)
DR-1 (BUT) ○ ○ ✓ Evaluation of influence on the corneal epithelium based on 
tear film Iipid layer grading
Schirmer l test (BUT) ○ ○ ✓ Lacrimation function based on tear volume
Pentacarn (Corneal 
thickness)
○ ○ ✓ Measurement of corneal thickness (influence on the  
corneal endothelium)
HRT II-RCM ○ ○ ✓ Morphological observation of the corneal stroma  
Evaluation of cell density
Adverse events ○ ○
Questionnaire to assess 
satisfaction with use
○ Assessment of irritating sensation and drop comfort upon 
instillation using a VAS
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study, they had favorable treatment compliance and each 
subject instilled the assigned study eye drops reliably.
Influence on the corneal epithelium
BUT
BUT scores measured by fluorescein staining before and 
after the 7 days of instillation were 13.8 ± 5.8 seconds 
and 11.9 ± 6.5 seconds, respectively, for eyes instilled 
with MFLX (MFLX group) and 13.6 ± 5.4 seconds and 
10.4 ± 6.0 seconds, respectively, for eyes instilled with 
LVFX (LVFX group). No significant change was observed 
in either group before or after the 7 days of instillation, and 
no statistically significant difference between the groups was 
observed in measurements after the 7 days of instillation 
(P = 0.4376, t-test).
BUT scores measured by DR-1 before and after the 7-day 
instillation were 29.0 ± 12.4 seconds and 22.8 ± 13.6 seconds, 
respectively, for the MFLX group and 29.4 ± 14.2 seconds 
and 22.3 ± 14.3 seconds, respectively, for the LVFX group. 
No significant change was observed in either group before or 
after the 7-days of instillation, and no statistically significant 
difference between groups was observed in measurements 
after the 7-days of instillation (P = 0.8795, t-test).
Grades of the tear film lipid layer using the DR-1 before 
and after the 7 days of instillation were 2.2 ± 0.5 and 2.8 ± 0.6, 
respectively, for the MFLX group and 2.1 ± 0.6 and 2.8 ± 0.4, 
respectively, for the LVFX group. No statistically significant 
difference between the groups was observed in grades after 
the 7-days of instillation (P = 0.9709, U-test). Changes in the 
grade were seen in 56.7% of subjects (17/30) in the MFLX 
group and in 66.7% of subjects (20/30) in the LVFX group, 
all changes were slight.
Schirmer I test scores before and after the 7 days of 
instillation were 20.9 ± 9.3 mm and 18.4 ± 11.2 mm, 
respectively, for the MFLX group and 19.3 ± 9.9 mm and 
19.2 ± 11.3 mm, respectively, for the LVFX group. No 
significant change was observed in either group before or 
after the 7 days of instillation, and no statistically significant 
difference between the groups was observed in scores after 
the 7 days of instillation (P = 0.3325, t-test).
Corneal epithelial defects according to area  
and density grading
The severity of superficial punctate keratitis (SPK) can be clas-
sified into nine grades according to the area and density (AD) 
grading which is the combination of the area (A) and density (D) Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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of the lesion stained as dots by fluorescein staining (Figure 1).7 In 
this study, the severity of corneal epithelial defects was evaluated 
using AD grading. Before instillation, corneal epithelial defects 
were not observed in any subject of either group, however, after 
the 7 days of instillation, corneal epithelial defects were observed 
in eight eyes of the subjects receiving MFLX and seven eyes of 
the subjects receiving LVFX. Among these subjects, four had 
mild epithelial defects in both eyes. AD grading of the 15 eyes 
was A1D1 for 14 eyes and A2D1 for the remaining eye. There 
was a statistically significant difference between groups before 
and after the instillation of MFLX (P = 0.0046, Fisher’s exact 
test). In addition, there was a statistically significant differ-
ence between groups before and after the instillation of LVFX 
(P = 0.0105, Fisher’s exact test). No statistically significant 
difference between the groups was observed in the incidence 
of epithelial defects (P = 0.675, t-test).
Influence on the corneal stroma
Cell density of the corneal stroma
Changes in cell density of the superficial, middle, and deep 
layers of the corneal stroma were observed.
Cell density of the superficial layer of the corneal 
stroma before and after the 7 days of instillation was 
643 ± 53 cell/mm2 and 633 ± 42 cell/mm2, respectively, for the 
MFLX group and 625 ± 42 cell/mm2 and 630 ± 36 cell/mm2, 
respectively, for the LVFX group. No statistically significant 
difference between the groups was observed in measurements 
after the 7 days of instillation.
Cell density of the middle layer of the corneal stroma before 
and after the 7 days of instillation was 488 ± 20 cell/mm2 and 
487 ± 22 cell/mm2, respectively, for the MFLX group and 
481 ± 26 cell/mm2 and 485 ± 25 cell/mm2, respectively, 
for the LVFX group. No statistically significant difference 
Group
Before
instillation
After
7 days
Before
instillation
After 7 days
P-
value
MFLX
LVFX
0/30
0/30
8/30
7/30
0.675
AD grading  of each eye
LVFX MFLX
After 7
days
Before
instillation
A0D0 A0D0 A1D1
A1D1
A1D1
A1D1
A1D1
A1D1
A1D1
A1D1
A0D0
A0D0
A0D0
A0D0
A0D0
A0D0
A0D0
A1D1
A1D1
A1D1
A1D1
A1D1
A1D1
A1D1 A0D0
A0D0
A0D0
A0D0
A0D0
A0D0
Figure 1 Corneal epithelial defects according to AD grading. After 7 days of instillation, corneal epithelial defects were observed in eight eyes of the subjects receiving 
MFLX and seven eyes of the subjects receiving LVFX. AD grading of the 15 eyes was A1D1 for 14 eyes and A2D1 for the remaining eye. No statistically significant difference 
between the groups was observed in the incidence of epithelial defects (P = 0.675, t-test).Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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between the groups was observed in measurements after the 
7 days of instillation.
Cell density of the deep layer of the corneal stroma before 
and after the 7 days of instillation was 428 ± 22 cell/mm2 and 
421 ± 21 cell/mm2, respectively, for the MFLX group and 
423 ± 27 cell/mm2 and 424 ± 25 cell/mm2, respectively, 
for the LVFX group. No statistically significant difference 
between the groups was observed in measurements after the 
7 days of instillation.
No significant change was observed in any layer before or 
after the 7 days of instillation, and no statistically significant 
difference between the groups was observed in measurements 
after the 7 days of instillation.
No Langerhans cells or inflammatory cells appeared in 
any of the layers.
Influence on the endothelium
Endothelial cell density
Endothelial cell density before and after the 7 days 
of instillation was 2817.9 ± 250.2 cell/mm2  and 
2778.0 ± 221.5 cell/mm2, respectively, for the MFLX group 
and 2816.1 ± 255.7 cell/mm2 and 2808.9 ± 261.9 cell/mm2, 
respectively, for the LVFX group. No significant change was 
observed in either group before or after the 7 days of instil-
lation, and no statistically significant difference between the 
groups was observed in measurements after the 7 days of 
instillation (P = 0.3195, t-test).
In addition, the coefficient of variation (CV) before 
and after the 7 days of instillation was 29.9% ± 5.3% and 
30.3% ± 5.1%, respectively, for the MFLX group and 
30.9% ± 6.7% and 29.7% ± 5.2%, respectively, for the 
LVFX group. No significant change was observed in either 
group before or after the 7 days of instillation, and no 
statistically significant difference between the groups was 
observed in measurements after the 7 days of instillation 
(P = 0.2295, t-test).
Measurement of corneal thickness
Corneal thickness measured with Pentacam before and 
after the 7 days of instillation were 561.9 ± 38.6 µm 
and 561.8 ± 39.2 µm, respectively, for the MFLX group and 
558.4 ± 37.6 µm and 559.5 ± 39.7 µm, respectively, for 
the LVFX group. No major change was observed in either 
group before or after the 7 days of instillation, and no 
statistically significant difference between the groups was 
observed in measurements after the 7 days of instillation 
(P = 0.6305, t-test).
Safety
No serious adverse events were reported in either group. 
No clinically important changes in general ocular findings 
were also noted.
Satisfaction with the study eye drops
All 30 subjects were asked to complete a questionnaire to 
assess their satisfaction with the study eye drops (irritating 
sensation and drop comfort upon instillation) using a VAS 
(0 to 100 mm). The mean value (95% confidence interval) 
of “irritating sensation” was 23.0 mm (14.1–31.8 mm) for 
MFLX and 31.0 mm (22.4–39.6 mm) for LVFX, showing 
a trend slightly favoring MFLX, however, no statistically 
significant difference was noted (P = 0.1658, Wilcoxon rank-
sum test). The mean value (95% confidence interval) of “drop 
comfort upon instillation” was 20.5 mm (12.9–28.1 mm) 
for MFLX and 25.7 mm (17.1–34.4 mm) for LVFX, also 
showing a trend slightly favoring MFLX, however, no 
statistically significant difference was noted (P = 0.4539, 
Wilcoxon rank-sum test).
Discussion
Although LVFX is a third-generation fluoroquinolone with a 
relatively broad spectrum of antibacterial activity, it has the 
disadvantage of being less active against gram-positive cocci. 
The minimum inhibitory concentrations of fourth-generation 
fluoroquinolones, MFLX and gatifloxacin (GFLX), against 
staphylococci and streptococci are higher than those of 
LVFX, and these fluoroquinolones are characterized by their 
broader antibacterial spectrum. In particular, since MFLX 
is known to have an approximately two- to three-fold lower 
ocular penetration than other antibacterial eye drops,3,4 this 
drug is expected to provide excellent clinical benefits. The 
superior penetration of MFLX is considered to be due to its 
unique physicochemical structure that combines high lipo-
philicity for enhanced corneal penetration with high aqueous 
solubility at physiological pH.3,4 However, it has not yet been 
clearly defined whether its excellent penetration could have 
some influence on the cornea.
The effect of fourth-generation fluoroquinolones, 
Zymar® (gatifloxacin ophthalmic solution, Allergan, Inc, 
Irvine, CA) and VIGAMOX® (moxifloxacin ophthalmic 
solution; Alcon Laboratories, Inc, Fort Worth, TX), on 
the corneal epithelial cells and intercellular space was 
investigated in an in vivo study using rabbits, evaluating 
the effect on tight junctions using ZO-1 immune staining. 
It was reported that in rabbits treated with VIGAMOX®, Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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corneal epithelial cell integrity was maintained with no 
effect on tight junctions, whereas in rabbits treated with 
Zymar®, decreased corneal epithelial cells and breakdown 
of tight junctions were observed, suggesting that benzalko-
nium chloride, an additive in Zymar®, was responsible for 
this effect.8 In the present study to objectively evaluate the 
in vivo effect of the fluoroquinolone eye drops in normal 
human eyes, although some subjects experienced mild 
corneal epithelial defects according to the AD grading, no 
statistically significant difference was observed between 
the two eye drops, LVFX and MFLX. Moreover, no obvious 
adverse effects of either drug on the corneal epithelium, 
stroma, and endothelium were noted in other evaluations. 
Furthermore, there were no issues concerning safety or 
subjective satisfaction with use of the study eye drops.
In vitro studies using cell cultures of human corneal 
keratocyte reported based on the proportion of concentration–
time exposures in which fluoroquinolones were cytotoxic, 
ciprofloxacin was the most cytotoxic to human corneal 
keratocyte (96%), followed by MFLX (67%), ofloxacin 
(62.5%), GFLX (58%), and LVFX (42%) concluding that 
fluoroquinolones may differ in their cytotoxic potential to 
human corneal keratocytes.2 However, this study revealed 
that there was no statistically significant difference between 
the groups before and after the 7 days of instillation. We also 
find that no Langerhans cells or inflammatory cells displayed 
in any of the stromal layers. These results suggest that both 
LVFX and MFLX affect no toxicity to the cornea. In addition, 
it is difficult to consider that MFLX has some influence on 
the corneal stroma under normal conditions. In the present 
study, we instilled the fluoroquinolone antibacterial eye 
drops into normal human eyes, and have concluded that these 
fluoroquinolone, used in a normal clinical setting, are less 
likely to cause such histological changes due to cytotoxic-
ity. Therefore, the use of fluoroquinolone eye drops on the 
normal cornea for sterilization before intraocular surgery or 
prophylaxis against postoperative infection should not raise 
concerns about cytotoxicity in corneal cells.
Only healthy volunteers were included in this study. 
Thus, there are limitations in applying our findings to 
patients with dry eyes or abnormal epithelia. Furthermore, 
our results may have been different if the frequency of 
instillation had been increased (eg, instillations every hour 
for corneal ulcers). In severe cases with corneal abnormali-
ties, the effects of antibiotics should be checked carefully. 
There may be limitations in comparing two antibiotics using 
some examinations with a high degree of variability in this 
study, such as BUT. However, there is no clear difference 
between two antibiotics in the series of our routine eye 
examinations here.
A randomized comparative study of MFLX 1% ophthal-
mic solution, in which the concentration is twice that of the 
product marketed in Japan, in patients with bacterial keratitis, 
the safety of MFLX was comparable to the comparators, 
OFLX 0.3% ophthalmic solution and tobramycin (1.33%)/
cephazolin (5%) ophthalmic solution, and the time to cure 
in non-exiting patients tended to be shorter for MFLX than 
for OFLX.9 Moreover, a study of MFLX 0.5%   ophthalmic 
solution instilled into the anterior chamber at the time 
of cataract surgery reported no statistically significant 
differences in corneal endothelial cell density after surgery 
or in corneal thickness after 1 month.10 It is inferred, based 
on the results of these studies, that high concentrations of 
MFLX in the corneal tissue would not cause any clinical 
adverse effects.
Conclusion
Although minor corneal SPK was observed in approximately 
25% of cases, no adverse corneal effects appeared between 
the 2 antibiotics upon examination with instillation of LVFX 
and MFLX three times daily over 7 days.
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